	Application No.	Applicant(s)
Notice of Allowability	09/758,957	HANSON ET AL.
	Examiner	Art Unit
	Jon D. Epperson	1639
	John D. Epperson	1039
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to <u>12 June 2006</u> .		
2. The allowed claim(s) is/are 67, 69 and 70 (renumbered 1-3).		
3. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).		
a)		
1. Certified copies of the priority documents have been received.		
2. Certified copies of the priority documents have been received in Application No		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) 🗌 hereto or 2) 🔲 to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s)	5 Dhatian of Informal D	lote at Analisation (DTO 452)
1. Notice of References Cited (PTO-892)	<u></u>	atent Application (PTO-152)
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. ☐ Interview Summary Paper No./Mail Da	te
 Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date 	·	
4. Examiner's Comment Regarding Requirement for Deposit of Biological Material	_	ent of Reasons for Allowance
	9.	

Application/Control Number: 09/758,957 Page 2

Art Unit: 1639

DETAILED ACTION

Status of the Application

1. Receipt is acknowledged of a response to a non-final rejection, which was dated on June 12, 2006.

Status of the Claims

2. Claims 63-70 were pending. Applicants canceled claims 63-66 and 68. In addition, Applicants amended claims 67 and 70. No claims were added. Therefore, claims 67, 69 and 70 are currently pending and examined on the merits.

Withdrawn Rejections

3. The new matter rejection under 35 U.S.C. 112, first paragraph over claims 63-66 and 68 is withdrawn in view of Applicants' cancellation of those claims. Support for the currently claimed compounds can be found, for example, in originally filed figures 9-12. The objection to claim 67 is also withdrawn in view of Applicants' amendments thereto.

Reasons for Allowance

4. The closest prior art of record does not teach or fairly suggest Applicants' claimed polypharmacophores or pharmaceutical compositions thereof. For example, although Dutta et al. (of record, see 12/29/04 office action) teach structurally similar compounds such as GBR12909 and GBR12935 (e.g., see Dutta et al., page 699, Chart 1), these compounds do not contain the currently claimed double bond or carboxylic acid groups. Furthermore, the prior art of record

Art Unit: 1639

does not teach or fairly suggest these modifications. Therefore, claims 67, 69 and 70 (renumbered 1-3) are allowed.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Salutation

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jon D Epperson whose telephone number is (571) 272-0808. The examiner can normally be reached Monday-Friday from 9:00 to 5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Peter Paras can be reached on (571) 272-4517. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (571) 272-1600.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Jon D. Epperson, Ph.D. June 18, 2006

JON EPPERSON, PH.D PATENT EXAMINER